

IN THE CLAIMS:

- 1-10. (Canceled without prejudice)
11. (Currently Amended) A method for treating psoriasis in a patient in need thereof comprising the step of administering a topical formulation,

wherein said formulation comprises epidermal growth factor as the sole active agent, and wherein the patient is a human being.
12. (Maintained) The method according to claim 11, wherein the topical formulation contains EGF in a concentration of 0.01 to 50 micrograms/gram formulation.
13. (Maintained) The method according to claim 11, wherein the topical formulation contains EGF in a concentration of 0.5 to 20 micrograms EGF/gram formulation.
14. (Canceled without prejudice) ~~The method according to claim 11, wherein the formulation further comprises an anti-inflammatory product.~~
15. (Currently Amended) ~~The~~ A method according to claim 11 for treating psoriasis in a patient in need thereof comprising the step of administering a topical formulation, wherein the formulation is a topical cream containing 0.1 to 3% (w/w) of sulfadiazine and 0.5 to 20 micrograms EGF/gram formulation.
16. (Maintained) The method according to claim 15, wherein the formulation comprises 10 µg EGF and 1% (w/w) sulfadiazine.
17. (Canceled without prejudice)
18. (New) A method for treating psoriasis in a patient in need thereof

Applicant: Rudi D. NEIRINCKX
Application No. 09/584,978
Attorney Docket No. 2502491-991110
(formerly 44334)

comprising the step of administering a topical formulation,

wherein said formulation comprises epidermal growth factor agent and an anti-inflammatory, and wherein the patient is a human being.

19. (New) The method of claim 15, wherein the formulation comprises 5 μ g EGF.